Why DaVita (DVA) is back in the spotlight
DaVita (DVA) is back under the microscope after recent analyst reports flagged flat treatment volumes, slower expected sales growth, and pressure on free cash flow margins, even as some ratings remain very positive.
See our latest analysis for DaVita.
DaVita’s share price has moved to US$153.06, with a 9.9% 1 month share price return and 26.1% 3 month share price return. Its 3 year total shareholder return of 96.2% contrasts with recent concerns over slower growth and tighter margins.
If this mixed picture around growth and cash flow has you looking beyond dialysis, it could be a good moment to scan 34 healthcare AI stocks as potential next ideas to research.
With DaVita trading around US$153 and sitting close to the average analyst price target, yet screening with an intrinsic discount of about 60%, you have to ask whether there is still a mispricing here or if future growth is already fully reflected in the share price.
Most Popular Narrative: 1% Overvalued
DaVita’s most followed narrative sets fair value at $151.71, just below the last close of $153.06, so the story really hinges on the earning power behind those cash flows.
The company's disciplined cost management and improved labor productivity have led to lower patient care costs per treatment, and with higher employee retention and training efficiencies expected to continue, this trend provides ongoing tailwinds for net margins.
Read the complete narrative. Read the complete narrative.
Want to see what is doing the heavy lifting in that valuation? The narrative leans on steady revenue gains, modest margin lift, and a future earnings multiple that stays restrained. The exact mix might surprise you.
Result: Fair Value of $151.71 (ABOUT RIGHT)
Have a read of the narrative in full and understand what's behind the forecasts.
However, persistently high mortality rates and reimbursement updates that lag cost inflation could still derail those margin and cash flow assumptions.
Find out about the key risks to this DaVita narrative.
Another View: Earnings Multiple Sends a Different Signal
Analysts and our fair value model place DaVita close to $151.71, yet the current P/E of 14.2x sits well below the US Healthcare average of 22.3x and the peer average of 35.5x. With a fair ratio of 24.5x, are markets still discounting execution and balance sheet risk too heavily?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and concern feels finely balanced, do not wait around. Check the data for yourself and weigh up 3 key rewards and 1 important warning sign.
Looking for more investment ideas?
If DaVita is on your radar, do not stop there. Let the data work for you and line up a few more candidates worth your time.
- Target potential value opportunities by reviewing our 48 high quality undervalued stocks that pair quality fundamentals with prices that could look appealing on closer inspection.
- Strengthen the defensive side of your portfolio by checking the 68 resilient stocks with low risk scores, focused on companies with more resilient risk profiles.
- Get ahead of the crowd by scanning our screener containing 25 high quality undiscovered gems, where solid fundamentals have not yet attracted widespread attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com